A Randomized, Double-blind, Placebo-controlled Phase I Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of SR750 (Prescription F1) in Chinese Healthy Subjects
Latest Information Update: 26 Apr 2025
At a glance
- Drugs SR 750 (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- Sponsors SIMR Biotech
Most Recent Events
- 22 Apr 2025 New trial record